Day 5 biopsy. Single embryo. Single baby.
Modern IVF protocol — stim, retrieval, ICSI, blastocyst culture to Day 5, trophectoderm biopsy with NGS PGT-A, freeze-all, single euploid embryo transfer. Higher live-birth rate per transfer, lower miscarriage risk, no twin pregnancy.
Live-birth rates per single euploid transfer in the best programmes are around 65% across age groups — consistent with international published cohorts. The chart compares this with fresh blastocyst transfer (no PGT) by age.
Adjust your inputs. The percentage is the probability of a live birth in the very next embryo transfer, based on published cohorts. Anchored on Franasiak 2014 and Forman 2013 for euploid eSET; SART 2022 for fresh blastocyst.
At your age, fresh blastocyst transfer (no PGT) gives ~37% — euploid eSET roughly doubles the per-transfer success rate.
Most labs in Kuwait now use NGS testing — modern 24-chromosome sequencing — and that part is right. The decision that matters more is when the biopsy happens and how many cells are tested. We biopsy on Day 5, taking 5–10 cells from the trophectoderm (the cells that become placenta, not the cells that become the baby). Some labs in Kuwait still biopsy on Day 3, taking a single cell from an 8-cell embryo. The same NGS, on the wrong day, with too few cells, removed at the wrong developmental stage.
Same test. Wrong day. Wrong cells.
The Scott et al 2013 paired randomized trial showed Day 3 biopsy reduced implantation rate by 39% per embryo. Day 5 trophectoderm biopsy showed no implantation impact. The biology is settled. The practice change is slower than the evidence.
Two weeks of stimulation, fifteen minutes of retrieval, six days of laboratory work, then a separate cycle for the transfer. Freeze-all is the default — the embryo and the uterus aren't ready in the same cycle.
10–14 days of injectable gonadotropins (FSH ± LH). Antagonist or PPOS protocol depending on response. Monitoring scans every 2–3 days. Trigger when leading follicles reach 17–18 mm.
36 hours after the trigger. 15-minute outpatient procedure under light sedation. Transvaginal ultrasound-guided aspiration. Average 8–15 mature oocytes for women under 38.
Single sperm injected directly into each mature egg under microscope. Standard for PGT-A cycles to avoid contamination from polyspermy. Fertilisation rates ~70–80%.
Embryos grow in time-lapse incubators for 5–6 days until they reach the blastocyst stage (~150 cells, differentiated into inner cell mass and trophectoderm). On Day 5 (or Day 6 for slower-developing embryos), 5–10 cells are taken from the trophectoderm — the placenta-lineage cells — for NGS PGT-A. The inner cell mass, which becomes the baby, is not touched.
Every biopsied blastocyst is vitrified within hours. Modern lab survival rates >98%. The freeze gives time for the genetic results to come back (7–14 days) and for the uterus to recover from the stimulation cycle, which improves implantation in the next cycle.
In a separate cycle, the endometrium is prepared (natural or HRT cycle), and a single euploid blastocyst is thawed and transferred. The procedure itself takes 5 minutes — no sedation needed. Pregnancy test 10 days later.
The genetic test (NGS) is the same in both cases. The question is when in the embryo's development the biopsy is taken, and how many cells are removed. Three reasons Day 5 trophectoderm biopsy is the modern standard:
The change to Day 5 biopsy required two enabling technologies: time-lapse incubators that don't disturb the embryos during 5 days of culture, and reliable vitrification that lets the embryo survive the 7–14 day wait for genetic results. Both have been clinical standard since the mid-2010s. Programmes that haven't changed haven't kept up with the lab science.
Patients sometimes ask for two embryos to increase the per-cycle chance of pregnancy. The arithmetic works against this when the embryo is already euploid: a single euploid blastocyst gives ~65% live-birth rate. Adding a second adds maybe 15 percentage points to the per-cycle pregnancy chance — but at a cost.
Pre-term birth, low birth weight, gestational diabetes, pre-eclampsia, NICU admission — all 3–5× more common in twin pregnancies. Twins are not a bonus; they are a complication.
Two euploid embryos transferred one at a time (in two cycles) gives a cumulative live-birth rate around 88%. Both at once in a single transfer gives ~75% — with twin-risk attached. Sequential single transfer wins on outcome and on safety.
When a twin pregnancy goes wrong, the alternatives — selective reduction, monoamniotic complications, severe pre-term — are difficult clinically and emotionally. Avoiding the situation is better than managing it.
The exception we discuss case-by-case: women with very few embryos, advanced maternal age, or repeated implantation failure where a double transfer changes the calculus. The default is single. The conversation is individual.
IVF is not the first answer for most fertility cases — it's the right answer for specific ones. The first consultation is a 30-minute review to decide whether you actually need it.
Day 3 biopsy was the standard before reliable vitrification was perfected, because the genetic results had to come back the same cycle as the transfer. Once vitrification became routine (mid-2010s), the entire field shifted to Day 5 biopsy + freeze-all. Some labs continued Day 3 biopsy because their freeze-thaw survival rates weren't reliable enough to trust frozen embryo transfers. Modern lab survival rates are >98%; the technical objection no longer holds. Practice change is slower than evidence — that's the entire reason this page exists.
Yes. The Scott et al 2013 paired randomized trial showed Day 5 trophectoderm biopsy had no measurable impact on implantation rate compared with non-biopsied controls. The biopsy samples cells from the placenta lineage, not from the inner cell mass that becomes the baby. Long-term outcome studies of children born from PGT-A cycles show no increased rate of birth defects, growth abnormalities, or developmental issues compared with conventional IVF.
One euploid embryo gives roughly the same per-transfer live-birth rate (~65% in the best programmes) as having three euploid embryos and transferring one. The number of embryos doesn't change the rate per transfer — it changes the cumulative chance over multiple attempts and your reserve for future siblings. A single euploid blastocyst is a strong starting point.
It happens — particularly in women over 40, where the proportion of euploid embryos per cycle drops sharply. The answer is usually a second stimulation cycle, sometimes with a different protocol or supportive supplements (CoQ10, DHEA in selected cases). For some women, accumulating euploid blastocysts across 2–3 banking cycles is the right strategy before any transfer. We discuss this honestly at consultation; the decision depends on your specific reserve and prior cycle response.
Yes — for any cycle with PGT-A (you have to wait for the genetic results), and increasingly as a default even without PGT-A. The stimulation itself raises oestradiol and progesterone to non-physiological levels that can shift the implantation window. Transferring in a separate, naturally-prepared cycle gives the uterus a clean start and improves implantation rates by ~10 percentage points in many studies. Modern vitrification survival is >98% — the freeze does not cost embryos.
It's a conversation, not a default. Twin pregnancy raises the risk of pre-term birth (sharply), low birth weight, gestational diabetes, pre-eclampsia, and NICU admission — typically 3–5× the rates of singleton pregnancy. The cumulative live-birth rate from sequential single euploid transfers is actually higher than from a double transfer (~88% over two single transfers vs ~75% from one double transfer). The safer arithmetic favours single. Exceptions exist — advanced age, very few embryos, repeated implantation failure — and those decisions are made case-by-case.
Pricing varies between clinics and depends heavily on stimulation drug doses and the lab add-ons selected. A standard cycle inclusive of monitoring, retrieval, ICSI, blastocyst culture, freeze-all, and the first FET typically falls within a published range that we confirm at consultation, with PGT-A as a separate per-embryo lab fee. We give a precise quote tailored to your specific protocol once we have your AMH and ovarian reserve.
Depends on your age and ovarian reserve. Women under 35 with normal AMH typically have enough euploid embryos from one stim cycle to support 2–3 transfers — most achieve a live birth in the first or second transfer. Women in their late 30s often need a second stim cycle to bank enough euploid embryos. Women over 42 often need 2–3 stim cycles before having even one euploid blastocyst to transfer. The calculator above estimates this for your age.
The argument on this page comes down to four figures. Each is a deliberate choice that compounds with the others.
Whether IVF is right for you, what protocol fits your reserve, what the cycle looks like, what it will cost. We'll go through your AMH, ultrasound, semen analysis if available, and prior workup. The decision is made together.